User login
Key clinical point: Tofacitinib induced rapid clinical response with sustained efficacy in nearly half of the pediatric and young adults with medically refractory inflammatory bowel disease (IBD) with a safety profile similar to that in adults.
Major finding: By the end of 12-week induction period, 81% of patients remained on tofacitinib therapy with 42.9% showing clinical response and 33.3% in steroid-free remission. By 52 weeks, 58.8% remained on tofacitinib and 41.2% showed clinical response and were in steroid-free remission. There were 11 serious adverse events requiring hospitalization including 1 instance of sterile intra-abdominal abscess. Instances of thrombi, zoster reactivation, or clinically significant hyperlipidemia were not observed.
Study details: Findings are from a retrospective chart review of 21 patients aged 21 years or younger who were initiated on tofacitinib after failing at least 1 previous biologic therapy.
Disclosures: The authors do not disclose funding source.
Source: Moore H et al. J Pediatr Gastroenterol Nutr. 2021 Jun 1. doi: 10.1097/MPG.0000000000003190.
Key clinical point: Tofacitinib induced rapid clinical response with sustained efficacy in nearly half of the pediatric and young adults with medically refractory inflammatory bowel disease (IBD) with a safety profile similar to that in adults.
Major finding: By the end of 12-week induction period, 81% of patients remained on tofacitinib therapy with 42.9% showing clinical response and 33.3% in steroid-free remission. By 52 weeks, 58.8% remained on tofacitinib and 41.2% showed clinical response and were in steroid-free remission. There were 11 serious adverse events requiring hospitalization including 1 instance of sterile intra-abdominal abscess. Instances of thrombi, zoster reactivation, or clinically significant hyperlipidemia were not observed.
Study details: Findings are from a retrospective chart review of 21 patients aged 21 years or younger who were initiated on tofacitinib after failing at least 1 previous biologic therapy.
Disclosures: The authors do not disclose funding source.
Source: Moore H et al. J Pediatr Gastroenterol Nutr. 2021 Jun 1. doi: 10.1097/MPG.0000000000003190.
Key clinical point: Tofacitinib induced rapid clinical response with sustained efficacy in nearly half of the pediatric and young adults with medically refractory inflammatory bowel disease (IBD) with a safety profile similar to that in adults.
Major finding: By the end of 12-week induction period, 81% of patients remained on tofacitinib therapy with 42.9% showing clinical response and 33.3% in steroid-free remission. By 52 weeks, 58.8% remained on tofacitinib and 41.2% showed clinical response and were in steroid-free remission. There were 11 serious adverse events requiring hospitalization including 1 instance of sterile intra-abdominal abscess. Instances of thrombi, zoster reactivation, or clinically significant hyperlipidemia were not observed.
Study details: Findings are from a retrospective chart review of 21 patients aged 21 years or younger who were initiated on tofacitinib after failing at least 1 previous biologic therapy.
Disclosures: The authors do not disclose funding source.
Source: Moore H et al. J Pediatr Gastroenterol Nutr. 2021 Jun 1. doi: 10.1097/MPG.0000000000003190.